rotation.to
Following this device: dark.
Free account
rotation.to
Sign in / Request free access
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

Who

Josh Wolfe

Director and 10% owner

Company insider

Files Form 4 as: Director and 10% owner, Eikon Therapeutics; Director and 10% owner, Shapeways Holdings; 10% owner, Aeva Technologies; 10% owner, Matterport, Inc./DE; 10% owner, Latch.

Every Form 4 they filed

In numbers

Trades disclosed
45
Buys
1
Sells
0
Bought
$10.0M
Sold
$0
Companies
5
Companies where not an officer
5
First trade
28 Sep 2021
Last trade
6 Feb 2026
Last filed
6 Feb 2026

Companies traded

Everywhere else they filed: board seats, 10% stakes, other companies
EIKN Eikon TherapeuticsDirector, 10% owner · Biotechnology · last 6 Feb 20261 buy · 0 sells
Shapeways HoldingsDirector, 10% owner · last 15 Jun 20230 buys · 0 sells
AEVA Aeva Technologies10% owner · Auto Parts & Dealers · last 5 Aug 20220 buys · 0 sells
Matterport, Inc./DE10% owner · last 18 Jan 20220 buys · 0 sells
Latch10% owner · Distributors & Wholesale · last 28 Sep 20210 buys · 0 sells

Activity over time

1 Feb – 1 Oct
01Feb 26Apr 26Jun 26Aug 26Oct 26

Buys above the line, sells below, each month.

Every trade

TradedCompanyWhatAmount
6 Feb 2026filed 6 Feb 2026EIKN Eikon Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code C—530,920filing
6 Feb 2026filed 6 Feb 2026EIKN Eikon Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code C—5,289,322filing
6 Feb 2026filed 6 Feb 2026EIKN Eikon Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code C—3,526,215filing
6 Feb 2026filed 6 Feb 2026EIKN Eikon Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code C—303,360filing
6 Feb 2026filed 6 Feb 2026EIKN Eikon Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code C—1,450,614filing
6 Feb 2026filed 6 Feb 2026EIKN Eikon Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code C—10,266,152filing
6 Feb 2026filed 6 Feb 2026EIKN Eikon TherapeuticsBiotechnologySEC FORM 4 Code C—2,387,705filing
6 Feb 2026filed 6 Feb 2026EIKN Eikon Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code C—10,000,000filing
6 Feb 2026filed 6 Feb 2026EIKN Eikon Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code C—7,807,026filing
6 Feb 2026filed 6 Feb 2026EIKN Eikon Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code C—2,502,252filing
6 Feb 2026filed 6 Feb 2026EIKN Eikon Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code C—796,380filing
6 Feb 2026filed 6 Feb 2026EIKN Eikon Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code C—530,920filing
6 Feb 2026filed 6 Feb 2026EIKN Eikon Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code C—5,289,322filing
6 Feb 2026filed 6 Feb 2026EIKN Eikon Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code C—3,526,215filing
6 Feb 2026filed 6 Feb 2026EIKN Eikon Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code C—303,360filing
6 Feb 2026filed 6 Feb 2026EIKN Eikon Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code C—1,450,614filing
6 Feb 2026filed 6 Feb 2026EIKN Eikon Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code C—10,266,152filing
6 Feb 2026filed 6 Feb 2026EIKN Eikon TherapeuticsBiotechnologySEC FORM 4 Code C—1,151,540filing
6 Feb 2026filed 6 Feb 2026EIKN Eikon TherapeuticsBiotechnologySEC FORM 4 Code C—2,155,765filing
6 Feb 2026filed 6 Feb 2026EIKN Eikon Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code C—10,000,000filing

Sectors

Health Care1

Buys in green, sells in red, by the company’s sector.

Related people

Tim KutzkeyDirector and 10% owner · 10% owner at Eikon Therapeutics, filing Form 4 there in the last year
Column Group IV GP, LP10% owner · 10% owner at Eikon Therapeutics, filing Form 4 there in the last year
Roy D. BaynesDirector · Chief Medical Officer at Eikon Therapeutics, filing Form 4 there in the last year
Alfred Lloyd Bowie Jr.Chief Financial Officer · Chief Financial Officer at Eikon Therapeutics, filing Form 4 there in the last year
Roger M. PerlmutterDirector and Officer · Insider at Eikon Therapeutics, filing Form 4 there in the last year